Kenichi Morikawa
Overview
Explore the profile of Kenichi Morikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, et al.
Liver Cancer
. 2023 Jun;
12(2):156-170.
PMID: 37325489
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus...
2.
Nakai M, Morikawa K, Sasaki T, Kohya R, Yoshida S, Hosoda S, et al.
J Gastroenterol
. 2023 Apr;
58(7):656-667.
PMID: 37103575
Background: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a...
3.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, et al.
J Med Virol
. 2023 Jan;
95(2):e28452.
PMID: 36597900
No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled...
4.
Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, et al.
Sci Rep
. 2022 Oct;
12(1):16800.
PMID: 36207368
De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight,...
5.
Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, et al.
World J Hepatol
. 2022 Sep;
14(7):1480-1494.
PMID: 36158914
Background: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. Aim:...
6.
Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, et al.
J Viral Hepat
. 2022 Aug;
29(11):976-985.
PMID: 36031873
Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current...
7.
Nakai M, Suda G, Ogawa K, Yoshida S, Hosoda S, Kubo A, et al.
PLoS One
. 2022 Jul;
17(7):e0270786.
PMID: 35776720
Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE)....
8.
Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, et al.
Hepatol Res
. 2022 Mar;
52(7):603-613.
PMID: 35352857
Aim: A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact...
9.
Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, et al.
Hepatol Res
. 2022 Mar;
52(7):586-596.
PMID: 35352445
Background & Aims: Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects...
10.
Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, et al.
Hepatol Res
. 2022 Feb;
52(6):508-521.
PMID: 35129841
Background And Aims: Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage...